0001209191-16-108927.txt : 20160316
0001209191-16-108927.hdr.sgml : 20160316
20160316182908
ACCESSION NUMBER: 0001209191-16-108927
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160314
FILED AS OF DATE: 20160316
DATE AS OF CHANGE: 20160316
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ONCOGENEX PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000949858
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 954343413
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 19820 NORTH CREEK PARKWAY
STREET 2: SUITE 201
CITY: BOTHELL
STATE: WA
ZIP: 98011
BUSINESS PHONE: 425-686-1500
MAIL ADDRESS:
STREET 1: 19820 NORTH CREEK PARKWAY
STREET 2: SUITE 201
CITY: BOTHELL
STATE: WA
ZIP: 98011
FORMER COMPANY:
FORMER CONFORMED NAME: SONUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19950825
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bencich John
CENTRAL INDEX KEY: 0001477056
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 033-80623
FILM NUMBER: 161510780
MAIL ADDRESS:
STREET 1: 2401 FOURTH AVENUE, SUITE 1050
CITY: SEATTLE
STATE: WA
ZIP: 98121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-03-14
0
0000949858
ONCOGENEX PHARMACEUTICALS, INC.
OGXI
0001477056
Bencich John
19820 NORTH CREEK PARKWAY
SUITE 201
BOTHELL
WA
98011
0
1
0
0
CFO
Common Stock
2016-03-14
4
M
0
3125
0.00
A
6698
D
Common Stock
2016-03-15
4
S
0
834
0.83
D
5864
D
Restricted Stock Unit (RSU)
2016-03-14
4
M
0
3125
0.00
D
2019-06-18
Common Stock
3125
9375
D
Stock Option (right to buy)
0.85
2016-03-14
4
A
0
112500
0.00
A
2026-03-14
Common Stock
112500
112500
D
Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
Each restricted stock unit (RSU) represents a contingent right to receive one share of the issuer's common stock at settlement.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of: (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open.
Pursuant to the terms of the options, 50% of the total shares underlying the option vest on the achievement of certain milestones, and 50% vest in monthly installments over 24 months commencing one month from achievement of one of the milestones. The options will lapse in full if achievement of one of the milestones is not met on or before December 31, 2016.
Sandra Thomson as attorney-in-fact for John Bencich
2016-03-16